Top Markets
Coin of the day
Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics, Inc.

OTLC
Rang in Aktien #30395
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage... Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.
Aktienkurs
$0.03834
Zuletzt synchronisiert: 2026-08-18
Marktkapitalisierung
$17.01M
Veränderung (1 Tag)
-4.15%
Veränderung (1 Jahr)
-24.82%
Land
US
Handel Oncotelic Therapeutics, Inc. (OTLC)

Kategorie

Kursverlauf für Oncotelic Therapeutics, Inc. (OTLC)
Höchster Schlusskurs: $0.04 am 2026-08-01

Niedrigster Schlusskurs: $1.13K am 1993-08-01
Kursverlauf der Aktie von Oncotelic Therapeutics, Inc. von 1993 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) -32.69%
2025 190.53%
2024 -20.32%
2023 -22.41%
2022 -69.52%
2021 -23.89%
2020 10.12%
2019 94.22%
2018 -42.06%
2017 -52.99%
2016 -55.78%
2015 -50.20%
2014 -33.92%
2013 -46.34%
2012 -62.10%
2011 -75.63%
2010 -81.77%
2009 63.41%
2008 -70.61%
2007 -50.93%
2006 16.57%
2005 -22.97%
2004 -35.60%
2003 628.33%
2002 -57.82%
2001 -63.45%
2000 -53.89%
1999 80.93%
1998 -47.29%
1997 -25.80%
1996 133.79%
1995 86.60%
1994 -25.42%
1993 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$527.89 35.09%
US
$996.61 51.72%
NL
$115.81 -20.44%
AU
$735.86 6.07%
CH
$257.75 14.92%
BE